Association of tenofovir exposure with kidney disease risk in HIV infection

Rebecca Scherzer, Michelle Estrella, Yongmei Li, Andy I. Choi, Steven G. Deeks, Carl Grunfeld, Michael G. Shlipak

Research output: Contribution to journalArticlepeer-review

285 Scopus citations


Objective: Despite widespread HAART use, HIV disease remains associated with increased risk of kidney disease. Whether tenofovir use is associated with higher risk of kidney disease is controversial. Design: We evaluated the association of cumulative and ever exposure to tenofovir on kidney outcomes in 10841 HIV-infected patients from the Veterans Health Administration who initiated antiretroviral therapy from 1997 to 2007. Methods: Cox proportional hazards and marginal structural models evaluated associations between tenofovir and time to first occurrence of proteinuria (two consecutive urine dipstick measurements 30mg/dl), rapid decline in kidney function (3ml/min per 1.73m annual decline), and chronic kidney disease (CKD; estimated glomerular filtration rate <60ml/min per 1.73m). Results: Median follow-up ranged from 3.9 years (proteinuria) to 5.5 years (CKD), during which 3400 proteinuria, 3078 rapid decline, and 533 CKD events occurred. After multivariable adjustment, each year of exposure to tenofovir was associated with 34% increased risk of proteinuria [95% confidence interval (CI) 25-45, P<0.0001], 11% increased risk of rapid decline (3-18, P=0.0033), and 33% increased risk of CKD (18-51, P<0.0001). Preexisting renal risk factors did not appear to worsen the effects of tenofovir. Other antiretroviral drugs showed weaker or inconsistent associations with kidney disease events. Among those who discontinued tenofovir use, risk of kidney disease events did not appear to decrease during follow-up. Conclusion: Tenofovir exposure was independently associated with increased risk for three types of kidney disease events, and did not appear to be reversible. Because subtle kidney function decline affects long-term morbidity and mortality, the balance between efficacy and probable adverse effects requires further study.

Original languageEnglish (US)
Pages (from-to)867-875
Number of pages9
Issue number7
StatePublished - Apr 24 2012


  • HIV
  • antiretroviral therapy
  • kidney disease
  • tenofovir

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Association of tenofovir exposure with kidney disease risk in HIV infection'. Together they form a unique fingerprint.

Cite this